Wednesday, 1 February 2017

Small interfering RNA (siRNA) Therapeutics - Competitive Landscape, Technology and Pipeline Insights, 2016

ResearchMoz added Latest Research Report titled " Small interfering RNA (siRNA) Therapeutics- Competitive Landscape, Technology and Pipeline Insights, 2016 " to it's Large Report database.

The Report, “Small interfering RNA (siRNA) Therapeutics - Competitive Landscape, Technology and Pipeline Insights, 2016” depicts the current pipeline scenario of siRNA therapies under development. Many targets which were difficult to reach by traditional small-molecule and protein have been identified by therapeutics based on RNA interference (RNAi). RNA interference (RNAi), a process in recovery Phase, is still keeping the expectations of the many mid Pharma companies at a higher end with blockbuster deals and adequate delivery technologies.

This report analysis the current frontrunners in siRNA therapies with leading technologies and major acquisitions and deals seen in past 3 years. Report highlights the 16 different types of technologies that have been used lately to enhance the siRNA development in different stages of development.

Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=655900

There are 15+ active companies dealing with 85+ siRNA therapies. Mostly siRNA is being studied for oncology area with 27 siRNA therapies under development by major pharma companies followed by 14 therapies for infectious diseases and 8 siRNA therapies in Ophthalmology. Currently 23 siRNA are in clinical stage of development with many mid-stage products.

Scope:
  • Coverage of global siRNA therapies under development across the globe
  • Competitive landscape of investigational products for key players and key therapy areas
  • The new siRNA report includes emerging technologies, drivers, barriers and eminent therapy areas focused by major companies.
  • Detailed information on product description and related stage of development, the mode of therapy, mechanism of action, development partner and technology information.
  • Report has highlighted the major collaborations, deals and acquisitions done by pharma companies to enrich their siRNA pipeline.
  • Report analyzes the different emerging delivery technologies by companies and products under development.
Read All Healthcare Market Research Reports @ http://www.researchmoz.us/healthcare-market-reports-56.html

Table of Content

Executive Summary
Small interfering RNA (siRNA) Therapeutics Overview
Introduction
Historical Development:
siRNA: Mode of Action
siRNA Technology &Delivery methods
SiRNA & its Applications in Gene Silencing:
Commercial Assessment
Drivers:
Barriers:
siRNA Therapeutics: Technology Analysis
siRNA Technology & Companies Current Scenario
Companies & Technologies
siRNA Technologies & Products
siRNA Therapeutics: Collaborations Analysis
siRNA Theraputics Collaborations & Deals
siRNA Therapeutics Licensing Deals:
siRNA Therapeutics Acquisition Deals
siRNA Therapeutics: Pipeline Analysis
siRNA Theraputics Therapy Area Analysis
siRNA Therpeutics Clinical Trials Analysis
siRNA Therapeutics &USFDA/EMA Designations
Pipeline Overview
Last Stage Products (Phase III)
Comparative Analysis
Mid Stage Products (Phase II)
Comparative Analysis

About ResearchMoz

ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG

No comments:

Post a Comment